A randomized trial of hte discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

Authors :: Lopez Bernaldo de Quiros, Juan C.
Miro, Jose M.
Pena, Jose M.
Podzamczer, Daniel
Alberdi, Juan C.
Martinez, Esteban
Cosin, Jaime
Claramonte, Xavier
Gonzalez, Juan
Domingo, Pere
Casado, Jose L.
Ribera, Esteban
Source :: The New England Journal of Medicine. Jan 18, 2001, Vol. 344 Issue 3, p159, 9 p.
Publication Year :: 2001
Abstract: HIV patients whose CD4 T cell counts increase to 200 or more as a result of antiretroviral therapy can stop taking drugs to prevent Pneumocystis carinii pneumonia (PCP). In a study of 714 such patients, none of the 300 patients who stopped taking drugs to prevent PCP developed PCP during a one- to two-year follow-up.

Subjects :: HIV infection -- Drug therapy
Pneumocystis carinii pneumonia -- Prevention

Tools